Is Hemostemix Inc (HMTXF) a Buy, Sell, or Hold?
OTC : HMTXF
Hemostemix Inc
$0.03824 USD
$0 (0.0%)
- Volume
- 6K
- Average Volume
- 4.16K
- Market Capitalization
- $7.56M
- P/E Ratio
- -2.74
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.10
- Year Low
- $0.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.24
| Source | Headline |
|---|---|
|
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain. Published in Circulation, Tresukosol et al evaluated VesCell™ in a phase I clinical trial of 24 patients suffering from chronic stable angina. newsfilecorp.com - 2026-07-08 10:08:00 |
|
Hemostemix Closes $360,000 First Tranche of Private Placement
Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement of units (the "Offering"), as originally disclosed on June 17, 2026. The Company raised aggregate gross proceeds of CDN$360,000 under the first tranche through the issuance of 7,200,000 units ("Units") at a price of CDN$0.05 per Unit. newsfilecorp.com - 2026-06-26 08:47:00 |
|
Hemostemix' $1,000,000 Private Placement and Update
Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches from the sale of Units at $0.05 each. Each Unit shall consist of one Common Share in the capital of the Company ("Common Share") and one half common share purchase warrant ("1/2 Warrant"), with each whole Warrant (2 x 1/2 Warrants) entitling the holder to acquire one Common Share at a price of $0.12 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below. newsfilecorp.com - 2026-06-17 17:22:00 |
